Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2003-11-28
2009-06-09
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S212010, C514S237800, C514S255030, C514S331000, C514S428000, C544S166000, C544S393000, C540S610000, C548S567000, C564S052000, C564S056000, C546S206000
Reexamination Certificate
active
07544716
ABSTRACT:
This invention relates to tetrahydro-naphthalene derivatives of formula (I)in which the variable groups are as defined in the specification and claims, and tautomeric and stereoisomeric forms and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD. The compounds, pharmaceutical compositions containing them, and methods of treatment using them are disclosed and claimed.
REFERENCES:
patent: 2004763 (1935-06-01), Lubs et al.
patent: 3142699 (1964-07-01), Wagner et al.
patent: 3239480 (1966-03-01), Windemuth et al.
patent: 3878206 (1975-04-01), Spencer et al.
patent: 4477389 (1984-10-01), Chen et al.
patent: 5453426 (1995-09-01), Jacobson et al.
patent: 6683107 (2004-01-01), Dollings et al.
patent: 6743814 (2004-06-01), Watanabe et al.
patent: 6841519 (2005-01-01), Nakatani et al.
patent: 7015233 (2006-03-01), Gomtsyan et al.
patent: 7045533 (2006-05-01), Brain et al.
patent: 7183411 (2007-02-01), Codd et al.
patent: 2004/0053890 (2004-03-01), Brain et al.
patent: 2004/0157865 (2004-08-01), Codd et al.
patent: 2004/0254188 (2004-12-01), Gomtsyan et al.
patent: 2004/0259875 (2004-12-01), Yura et al.
patent: 2005/0043351 (2005-02-01), Gomtsyan et al.
patent: 2005/0165046 (2005-07-01), Hulme et al.
patent: 2005/0165049 (2005-07-01), Hulme et al.
patent: 2006/0058342 (2006-03-01), Firoodznia
patent: 2006/0128704 (2006-06-01), Tajimi et al.
patent: 2006/0142333 (2006-06-01), MacDonald et al.
patent: 2006/0258742 (2006-11-01), Yura et al.
patent: 0050387 (2000-08-01), None
patent: 0055152 (2000-09-01), None
patent: 0075106 (2000-12-01), None
patent: 02072536 (2002-09-01), None
patent: 03095420 (2003-11-01), None
Skogval et. al. Pulmonary Pharmacology & Therapeutics 2007, 20, 273-280.
Szallasi, A. et. al. Trends in Molecular Medicine 2006, 12, 545-554.
Ohta et. al. Biochemical Pharmacology 2005, 71, 173-187.
Nijhuis et. al. Synthesis 1987, 641-645.
Holland et. al. Synthesis 2002, 2379-2382.
Bachmann et. al. Macromolecular Chemistry & Physics 2001, 202, 3410-3419.
Walpole et. al Journal of Medicinal Chemistry 1994, 37, 1942-1954.
Martin, Yvonne C. et. al. “Do Structurally Similar Molecules Have Similar Biological Activity?” Journal of Medicinal Chemistry 2002, 45, 4350-4358.
Swanson et. al. “Identification and Biological Evaluation of 4-(3- Trifluoromethylpyridin-2-yl)piperazine-1-carboxylic Acid (5-Trifluoromethylpyridin-2-yl)amide, a High Affinity TRPV1 (VR1) Vanilloid Receptor Antagonist” Journal of Medicinal Chemistry 2005, 48, 1857-1872.
Arpad Szallasi and Clare J Fowler “After a decade of intravesical vanilloid therapy: still more questions than answers” The Lancet Neurology vol. 1 Jul. 2002 167-172.
Slocombe et al., Phogene Derivatives, “The Preparation of Isocynates, Carbamyl Chlorides, and Cyanuric Acid,” Contribution from the Phosphate Laboratories, Phosphate Division, Monsanto Chemical Company, vol. 72, 1950, pp. 1888-1891.
Daniher, “The Sulfation of Hyrdoxamic Acids,” J. Org. Chem., vol. 34, No. 10, Oct. 1969, pp. 2908-2911.
Kurita et al., “Trichloromethyl Chloroformate, Reaction with Amines, Amino Acids, and Amino Alcohols,” J. Org. Chem., vol. 41, No. 11, 1976, pp. 2070-2071.
Bonjouklian et al., “Versatile Allene and Carbon Dioxide Equivalents for the Diels-Alder Reaction,” J. Org. Chem., vol. 42, No. 25, 1977, pp. 4095-4103.
Fuller et al., “Bronchoconstrictor response to inhaled capsaicin in humans,” J Appl Physiol. Apr. 1985;58(4):1080-4.
de Groat et al., “Mechanisms underlying the recovery of urinary bladder function following spinal cord injury,” Journal of the Autonomic Nervous System, 30 (1990) S71-S78.
Belvisi et al., “Capsazepine as a selective antagonist of capsaicin-induced activation of C-fibres in guinea-pig bronchi,” Eur-J-Pharmacol. May 14, 1992; 215(2-3): : 341-4.
Midgren et al., “Capsaicin-induced cough in humans,” Am Rev Respir Dis. Aug. 1992;146(2):347-51.
Laude et al., “A comparative study of the effects of citric acid, capsaicin and resiniferatoxin on the cough challenge in guinea-pig and man,” Pulm Pharmacol. Sep. 1993;6(3):171-5.
Maggi et al., “A comparison of capsazepine and ruthenium red as capsaicin antagonists in the rat isolated urinary bladder and vas deferens,” Br-J-Pharmacol. Mar. 1993; 108(3): 801-5.
Szallasi et al., “Competitive inhibition by capsazepine of [3H]resiniferatoxin binding to central (spinal cord and dorsal root ganglia) and peripheral (urinary bladder and airways) vanilloid (capsaicin) receptors in the rat,” J Pharmacol Exp Ther. Nov. 1993;267(2):728-33.
Cheng et al., “Effect of capsaicin on micturition and associated reflexes in chronic spinal rats,” Brain Res. Apr. 24, 1995:678(1-2):40-8.
Lalloo et al., “Capsazepine inhibits cough induced by capsaicin and citric acid but not by hypertonic saline in guinea pigs,” J Appl Physiol. Oct. 1995;79(4):1082-7.
Szallasi et al., “Resiniferatoxin binding to vanilloid receptors in guinea pig and human airways,” Am J Respir Crit Care Med. Jul. 1995;152(1):59-63.
Kanazawa et al., “Subthreshold concentration of endothelin-1-enhanced, capsaicin-induced bronchoconstriction in anaesthetized guinea-pigs,” Eur Respir J 1998; 12: 1307-1312.
Belfield et al., “Synthesis of Meta-substituted Aniline Derivatives by Nucleophillic Substitution,” Tetrahedron 55 (1999) 13285-13300.
Cheng et al., “Effect of capsaicin on the micturition reflex in normal and chronic spinal cord-injured cats,” Am J Physiol. Sep. 1999;277(3 Pt 2):R786-94.
Lepore et al., “Use of the Kaiser Oxime Resin in the Solid-Phase Synthesis of 3-Aminobenzisoxazoles,” J. Org. Chem. 1999, 64, 4547-4550.
de Ridder et al., “Vanilloids and the overactive bladder,” BJU International (2000), 86, 172-180.
Doherty et al., “Capsaicin responsiveness and cough in asthma and chronic obstructive pulmonary disease,” Thorax. Aug. 2000;55(8):643-9.
Wahl et al., “Iodo-Resiniferatoxin, a New Potent Vanilloid Receptor Antagonist,” Mol Pharmacol. Jan. 2001;59(1):9-15.
Birder et al., “Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1,” Nat Neurosci, Sep. 2002;5(9):856-60.
Fowler, “Bladder afferents and their role in the overactive bladder,” Urology. May 2002:59(5 Suppl 1):37-42.
Jia et al., “Anandamide induces cough in conscious guinea-pigs through VR1 receptors,” British Journal of Pharmacology (2002) 137, 831-836.
Ost et al., “Topography of the vanilloid receptor in the human bladder: more than just the nerve fibers,” J Urol. Jul. 2002;168(1):293-7.
Belvisi, “Airway sensory innervation as a target for novel therapies: an outdated concept?,” Curr Opin Pharmacol. Jun. 2003;3(3):239-43.
Belvisi, “Sensory nerves and airway inflammation: role of A delta and C-fibres,” Pulm Pharmacol Ther. 2003;16(1):1-7.
Wang et al., “High-Affinity Partial Agonists of the Vanilloid Receptor,” Mol Pharmacol. Aug. 2003;64(2):325-33.
Trevisani et al., “Antitussive activity of iodo-resiniferatoxin in guinea pigs,” Thorax. Sep. 2004;59(9):769-72.
Mohapatra et al., “Regulation of Ca2+-dependent desensitization in the vanilloid receptor TRPV1 by calcineurin and cAMP-dependent protein kinase,” J Biol Chem. Apr. 8, 2005;280(14):13424-32. Epub Feb. 3, 2005.
Birder,
Fujishima Hiroshi
Kokubo Toshio
Masuda Tsutomu
Mogi Muneto
Moriwaki Toshiya
Baker & Botts L.L.P.
Desai Rita J
O'Dell David K
Xention Limited
LandOfFree
Tetrahydro-naphthalene derivatives as vanilloid receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydro-naphthalene derivatives as vanilloid receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydro-naphthalene derivatives as vanilloid receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4056042